Does the media prefer APGE or SNDX?

In the previous week, Apogee Therapeutics had 5 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Apogee Therapeutics' score of 0.65 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SNDX or IMVT?

In the previous week, Immunovant had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Immunovant and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Immunovant's score of 0.46 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SNDX or RYTM?

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Syndax Pharmaceuticals' score of 0.88 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SNDX or MIRM?

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Mirum Pharmaceuticals' score of 0.78 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or PTCT?

In the previous week, PTC Therapeutics had 14 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 20 mentions for PTC Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat PTC Therapeutics' score of 0.57 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Syndax Pharmaceuticals (SNDX) Competitors

$23.69 +0.80 (+3.49%)

As of 10:39 AM Eastern

Compare

SNDX vs. APGE, IMVT, RYTM, MIRM, and PTCT

Should you buy Syndax Pharmaceuticals stock or one of its competitors? MarketBeat compares Syndax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Syndax Pharmaceuticals include Apogee Therapeutics (APGE), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.

How does Syndax Pharmaceuticals compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

In the previous week, Apogee Therapeutics had 5 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Apogee Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Apogee Therapeutics' score of 0.65 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Apogee Therapeutics' return on equity of -32.64% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

79.0% of Apogee Therapeutics shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Apogee Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Syndax Pharmaceuticals	$172.35M	12.18	-$285.42M	-$2.79	N/A

Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Apogee Therapeutics presently has a consensus price target of $121.25, suggesting a potential downside of 9.46%. Syndax Pharmaceuticals has a consensus price target of $42.55, suggesting a potential upside of 79.59%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Syndax Pharmaceuticals beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Immunovant?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Immunovant had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 10 mentions for Immunovant and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Immunovant's score of 0.46 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Immunovant's return on equity of -65.66% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Immunovant	N/A	-65.66%	-59.88%

Syndax Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	12.18	-$285.42M	-$2.79	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Syndax Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Syndax Pharmaceuticals currently has a consensus target price of $42.55, indicating a potential upside of 79.59%. Immunovant has a consensus target price of $39.70, indicating a potential upside of 3.36%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Syndax Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

47.1% of Immunovant shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Syndax Pharmaceuticals beats Immunovant on 10 of the 16 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Syndax Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Syndax Pharmaceuticals' score of 0.88 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals presently has a consensus price target of $42.55, indicating a potential upside of 79.59%. Rhythm Pharmaceuticals has a consensus price target of $138.29, indicating a potential upside of 27.39%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Syndax Pharmaceuticals' net margin of -111.88%. Rhythm Pharmaceuticals' return on equity of -203.25% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Rhythm Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	12.18	-$285.42M	-$2.79	N/A
Rhythm Pharmaceuticals	$189.76M	39.20	-$196.54M	-$3.13	N/A

Summary

Rhythm Pharmaceuticals beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Mirum Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	12.18	-$285.42M	-$2.79	N/A
Mirum Pharmaceuticals	$521.31M	14.02	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 5 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Mirum Pharmaceuticals' score of 0.78 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Syndax Pharmaceuticals presently has a consensus price target of $42.55, suggesting a potential upside of 79.59%. Mirum Pharmaceuticals has a consensus price target of $143.40, suggesting a potential upside of 19.60%. Given Syndax Pharmaceuticals' higher probable upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Syndax Pharmaceuticals has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

Syndax Pharmaceuticals has a net margin of -111.88% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

Syndax Pharmaceuticals (NASDAQ:SNDX) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

PTC Therapeutics has a net margin of -22.58% compared to Syndax Pharmaceuticals' net margin of -111.88%. Syndax Pharmaceuticals' return on equity of -256.65% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Syndax Pharmaceuticals currently has a consensus target price of $42.55, suggesting a potential upside of 79.59%. PTC Therapeutics has a consensus target price of $91.57, suggesting a potential upside of 14.83%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Syndax Pharmaceuticals is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

PTC Therapeutics has higher revenue and earnings than Syndax Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	12.18	-$285.42M	-$2.79	N/A
PTC Therapeutics	$1.73B	3.82	$682.64M	-$2.33	N/A

Syndax Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

In the previous week, PTC Therapeutics had 14 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 20 mentions for PTC Therapeutics and 6 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat PTC Therapeutics' score of 0.57 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Syndax Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNDX vs. The Competition

Export

Metric	Syndax Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.10B	$3.64B	$6.76B	$12.50B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-8.49	20.96	26.93	24.41
Price / Sales	12.18	313.81	586.18	117.36
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	32.01	8.50	10.94	6.33
Net Income	-$285.42M	$23.83M	$3.58B	$330.66M
7 Day Performance	1.94%	-3.12%	-2.10%	-0.66%
1 Month Performance	29.81%	6.61%	3.21%	-0.14%
1 Year Performance	140.51%	48.58%	26.34%	20.16%

Syndax Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNDX Syndax Pharmaceuticals	2.6812 of 5 stars	$23.69 +3.5%	$42.55 +79.6%	+138.7%	$2.10B	$172.35M	N/A	110
APGE Apogee Therapeutics	1.8695 of 5 stars	$133.57 0.0%	$121.25 -9.2%	+250.9%	$8.27B	N/A	N/A	91	Short Interest Decrease
IMVT Immunovant	2.0853 of 5 stars	$39.73 -3.3%	$39.70 -0.1%	+113.5%	$8.16B	N/A	N/A	120
RYTM Rhythm Pharmaceuticals	3.2732 of 5 stars	$109.06 -5.6%	$138.29 +26.8%	+24.0%	$7.46B	$189.76M	N/A	140	Positive News Gap Down
MIRM Mirum Pharmaceuticals	2.5576 of 5 stars	$121.82 -4.6%	$143.40 +17.7%	+126.1%	$7.43B	$521.31M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNDX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. APGE, IMVT, RYTM, MIRM, and PTCT

How does Syndax Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Syndax Pharmaceuticals compare to Immunovant?

Summary

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syndax Pharmaceuticals (SNDX) Competitors

SNDX vs. APGE, IMVT, RYTM, MIRM, and PTCT

How does Syndax Pharmaceuticals compare to Apogee Therapeutics?

Does the media prefer APGE or SNDX?

Is APGE or SNDX more profitable?

Do insiders and institutionals hold more shares of APGE or SNDX?

Which has higher valuation and earnings, APGE or SNDX?

Which has more volatility and risk, APGE or SNDX?

Do analysts recommend APGE or SNDX?

Summary

How does Syndax Pharmaceuticals compare to Immunovant?

Does the media refer more to SNDX or IMVT?

Is SNDX or IMVT more profitable?

Which has preferable valuation and earnings, SNDX or IMVT?

Which has more volatility and risk, SNDX or IMVT?

Do analysts recommend SNDX or IMVT?

Do institutionals & insiders believe in SNDX or IMVT?

Summary

How does Syndax Pharmaceuticals compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, SNDX or RYTM?

Does the media prefer SNDX or RYTM?

Do analysts recommend SNDX or RYTM?

Is SNDX or RYTM more profitable?

Which has better earnings & valuation, SNDX or RYTM?

Summary

How does Syndax Pharmaceuticals compare to Mirum Pharmaceuticals?

Which has stronger valuation & earnings, SNDX or MIRM?

Does the media prefer SNDX or MIRM?

Do analysts recommend SNDX or MIRM?

Which has more risk and volatility, SNDX or MIRM?

Is SNDX or MIRM more profitable?

Summary

How does Syndax Pharmaceuticals compare to PTC Therapeutics?

Is SNDX or PTCT more profitable?

Do analysts prefer SNDX or PTCT?

Which has better earnings and valuation, SNDX or PTCT?

Which has more risk & volatility, SNDX or PTCT?

Does the media favor SNDX or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX vs. The Competition

Syndax Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools